Biogen’s Tecfidera follow-up Vumerity hit the market late last year, but eight months into the launch, the new multiple sclerosis drug is yet to meaningfully take off. The drug generated only $11 ...
Biogen BIIB announced that the European Commission (EC) has approved its marketing authorization application for its next-generation, oral multiple sclerosis drug, Vumerity (diroximel fumarate) for ...
“With MS, finding the right treatment option is as much about managing the clinical aspects of the disease as it is about how treatment fits into a person’s life,” said Simon Faissner, M.D., PhD, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Results from the EVOLVE-MS-1 study show Vumerity was ...
Share on Pinterest Doctors expect people with MS will stick to their treatments with Vumerity because it has fewer side effects. Getty Images The FDA has approved Vumerity, a new drug to treat ...
Biogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to its blockbuster Tecfidera that promises to be less likely to cause gastrointestinal side ...
Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis The MHRA has granted marketing authorisation for diroximel fumarate as oral treatment for ...
A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis The Committee for Medicinal Products for Human Use (CHMP) has recommended Vumerity ...
– VUMERITY, a New Oral Treatment Option for Relapsing Forms of MS, Offers a Combination of Well-Characterized Efficacy, Safety and Tolerability – CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 ...
About VUMERITY® (diroximel fumarate) VUMERITY is an oral fumarate with a distinct chemical structure from TECFIDERA ® (dimethyl fumarate), approved in the U.S. for the treatment of relapsing forms of ...
Biogen’s Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium (SMC) as an oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most ...
This content is sponsored by Biogen and is intended for U.S. audiences only. Any other present or future content posted by the contributor, not expressly designated as ‘Biogen-sponsored content’ is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results